Last reviewed · How we verify
NCT05803070
Topical Cetirizine in Treatment of Localized Alopecia Areata
trial testing Topical Cetirizine 1 % in Alopecia Areata in 59 participants. Status unknown.
1 September 2024
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 59 |
| Start date | 1 September 2023 |
| Primary completion | 1 September 2024 |
| Estimated completion | 1 October 2024 |
Drugs / interventions tested
- Topical Cetirizine 1 % — full drug profile →
- Topical betamethasone valerate 0.1% — full drug profile →
Conditions studied
- Alopecia Areata — all drugs for Alopecia Areata →
Sponsor
Assiut University
Who can join
Adults 12 to 75, any sex, with Alopecia Areata. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluate and compare the efficacy and safety of topical cetirizine 1%, versus topical betamethasone valerate 0.1% in the treatment of localized alopecia areata.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Function and Role of Histamine H<sub>1</sub> Receptor in the Mammalian Heart.
Neumann J, Hofmann B, Kirchhefer U, Dhein S, et al · · 2023 · cited 12× · PMID 37242517 · DOI 10.3390/ph16050734
Verify or expand the search:
- PubMed search for NCT05803070
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alopecia Areata
Currently open trials in the same condition.
- NCT07242638 — Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome · Phase 2 · recruiting
- NCT07311564 — A Study of LAD603 in Adults With Alopecia Areata · Phase 2 · recruiting
- NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
- NCT07205159 — A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. · Phase 1 · recruiting
- NCT06747611 — Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata · Phase 2 · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05803070 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 7 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05803070.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing